Analytical Data
-
Gene name
AKTIP
- Application
-
Alternative Names
AKTIP；FTS；AKT-interacting Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H8T0
-
Expression Region
1-292aa
-
AA Sequence
MNPFWSMSTSSVRKRSEGEEKTLTGDVKTSPPRTAPKKQLPSIPKNALPITKPTSPAPAAQSTNGTHASYGPFYLEYSLLAEFTLVVKQKLPGVYVQPSYRSALMWFGVIFIRHGLYQDGVFKFTVYIPDNYPDGDCPRLVFDIPVFHPLVDPTSGELDVKRAFAKWRRNHNHIWQVLMYARRVFYKIDTASPLNPEAAVLYEKDIQLFKSKVVDSVKVCTARLFDQPKIEDPYAISFSPWNPSVHDEAREKMLTQKKPEEQHNKSVHVAGLSWVKPGSVQPFSKEEKTVAT
-
Molecular Weight
49.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AKTIP (AKT Interaction Protein) is a novel protein that has garnered attention in the field of molecular biology and cancer research due to its significant role in cellular signaling pathways, particularly those related to the AKT signaling cascade. AKT, also known as Protein Kinase B, is a crucial mediator of cell growth, survival, and metabolism, and its dysregulation is often implicated in various cancers. Research has indicated that AKTIP interacts directly with AKT, influencing its activity and stability, and thereby affecting downstream processes that contribute to tumor progression. The understanding of AKTIP's function is pivotal, as it may serve as a potential biomarker for cancer diagnosis and prognosis, as well as a therapeutic target. Various studies have focused on elucidating the molecular mechanisms by which AKTIP modulates AKT activity and its involvement in cancer cell proliferation and resistance to chemotherapy. Furthermore, the exploration of AKTIP’s role in other diseases and physiological conditions continues to expand, highlighting its importance beyond oncology. Overall, the investigation of AKTIP and its associated pathways promises to provide valuable insights into cancer biology and could lead to innovative approaches in targeted therapies.
